The role of the IL-1β antibody canakinumab (CNK) is less clear, due to both the lack of experience with its use as interventional therapy in MAS and the occurrence of instances of MAS, recorded as adverse event, in the randomized clinical trials that led to its registration in sJIA [19, 20]. This evidence concerns the gene IL1B and macrophage activation syndrome.